This author has yet to write their bio.Meanwhile lets just say that we are proud meritemea contributed a whooping 21 entries.
Entries by meritemea
SOUTH JORDAN, Utah, July 06, 2016 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has acquired DFINE, Inc. headquartered in San Jose, California, in a merger transaction through which DFINE has become a wholly-owned subsidiary […]
San Jose, Calif. January 23, 2015 — DFINE, Inc.,announced today that the first two patients have been enrolled in the STARRT Clinical Trial at Providence Sacred Heart Medical Center, Spokane WA. The multi-center trial is the first prospective study to evaluate the treatment of painful metastatic lesions with STAR Targeted Radiofrequency Ablation (t-RFA) and Radiofrequency Targeted Vertebral Augmentation (RF-TVA) prior to or following radiation therapy.
Praveen R. Anchala, MD, Winston D. Irving, MD, Travis J. Hillen, MD, Michael V. Friedman, MD, Bassem A. Georgy, MD, Douglass, M. Coldwell, MD, PhD, Nam D. Tran, MD, PhD, Frank D. Vrionis MD, PhD, Allan Brook, MD, and Jack W. Jennings, MD, PhD Article presented the reality of fast and lasting relief from painful […]
MAASTRICHT, The Netherlands— Merit Medical EMEA today launched its new website, www.MeritEMEA.com. The new website is a key component of the company’s vision to be the most customer-focused company in healthcare. The eye-catching, user-friendly site was built with Merit Medical’s customers in mind, prominently featuring the company’s diverse range of products. In addition, www.MeritEMEA.com provides […]
San Jose, Calif. – Feb. 18, 2014 –Two studies presented at the American Society of Spine Radiology (ASSR) 2014 Annual Symposium in Miami highlighted the benefits of Targeted Radiofrequency Ablation? (t-RFA) therapy with the DFINE STAR? Tumor Ablation System. The studies demonstrated the ability of the STAR System to provide significant pain relief to patients […]
DFINE, INC. RECEIVES CE MARK APPROVAL FOR STAR? TUMOR ABLATION SYSTEM European Launch at CIRSE Annual Congress SAN JOSE, Calif., Sept. 12, 2013 — DFINE, Inc., a fast-growing market leader in the treatment of spinal diseases, today announced it has received CE Mark approval for the STAR? Tumor Ablation System for treatment of painful metastatic […]